<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article233</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/EINSTEIN_CHOICE" style="display:block; margin-bottom:10px;">EINSTEIN CHOICE Original</a></li>
<h2><strong>EINSTEIN CHOICE</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Rivaroxaban for the Prevention of Venous Thromboembolism". The New England Journal of Medicine. 2017.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with venous thromboembolism and in equipoise for continued anticoagulation, is rivaroxaban more effective than aspirin in preventing recurrent thrombosis without an increase in bleeding risk?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Rivaroxaban, either at a treatment dose of 20 mg or thromboprophylactic dose of 10 mg, was more effective than aspirin at preventing recurrent venous thromboembolism without a significant increase in bleeding rates.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
The results of this study could inform future guidelines by providing an alternative to aspirin for extended VTE treatment, particularly in patients with equipoise regarding continued anticoagulation.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, randomized, placebo-controlled phase 3 trial<br/>
- N=3,396 patients with venous thromboembolism<br/>
- Interventions:<br/>
  * Rivaroxaban 20 mg PO daily (n=1,107)<br/>
  * Rivaroxaban 10 mg PO daily (n=1,127)<br/>
  * Aspirin 100 mg PO daily (n=1,131)<br/>
- Mean follow-up: 351 days<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion criteria: Patients 18 years or older with symptomatic proximal deep-vein thrombosis or pulmonary embolism who completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation.<br/>
- Exclusion criteria: Contraindication to continued anticoagulant therapy, need for extended therapeutic-dose anticoagulant agents, antiplatelet therapy, or creatinine clearance less than 30 ml per minute.<br/>
- Baseline characteristics: Similar across all three groups.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients were assigned to receive rivaroxaban (20 mg or 10 mg) or aspirin (100 mg) once daily with food for up to 12 months.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary efficacy outcome: Symptomatic recurrent fatal or nonfatal VTE, and unexplained death where PE could not be ruled out.<br/>
  * 20 mg rivaroxaban: 17 events (1.5%)<br/>
  * 10 mg rivaroxaban: 13 events (1.2%)<br/>
  * Aspirin: 50 events (4.4%)<br/>
- Principal safety outcome: Major bleeding<br/>
  * 20 mg rivaroxaban: 6 events (0.5%)<br/>
  * 10 mg rivaroxaban: 5 events (0.4%)<br/>
  * Aspirin: 3 events (0.3%)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The study excluded patients who required ongoing therapeutic doses of anticoagulants, thus its findings may not apply to this population.<br/>
- Study duration limited to up to 12 months; longer-term outcomes remain unknown.<br/>
- Noninferiority of 10 mg rivaroxaban to 20 mg rivaroxaban not established due to study power.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The study was funded by Bayer Pharmaceuticals.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017;376:1211-1222. DOI: 10.1056/NEJMoa1700518
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
